| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | J Wolf | |
| S C Chen | |||
| K A Thursky | |||
| B W Teh | |||
| L Cooley | |||
| C Dendle | |||
| C Boutlis | |||
| P2860 | cites work | Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients | Q24243871 |
| Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation | Q24652970 | ||
| Evaluation of PCR in bronchoalveolar lavage fluid for diagnosis of Pneumocystis jirovecii pneumonia: a bivariate meta-analysis and systematic review | Q26865669 | ||
| Pneumocystis jirovecii in general population | Q28238490 | ||
| Pneumocystis jiroveci pneumonia: high-resolution CT findings in patients with and without HIV infection | Q28267338 | ||
| Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS | Q28268439 | ||
| Immunocompetent hosts as a reservoir of pneumocystis organisms: histological and rt-PCR data demonstrate active replication | Q30887202 | ||
| Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition | Q30933878 | ||
| A prospective randomized trial comparing the toxicity and safety of atovaquone with trimethoprim/sulfamethoxazole as Pneumocystis carinii pneumonia prophylaxis following autologous peripheral blood stem cell transplantation | Q33330260 | ||
| Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide | Q33341259 | ||
| Severe pulmonary adverse effects in lymphoma patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus rituximab. | Q33691650 | ||
| Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes | Q33856426 | ||
| High prevalence of dihydropteroate synthase mutations in Pneumocystis jirovecii isolated from patients with Pneumocystis pneumonia in South Africa | Q33909311 | ||
| Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states | Q34033833 | ||
| Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients | Q34754990 | ||
| Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review | Q34762420 | ||
| Development and evaluation of a quantitative, touch-down, real-time PCR assay for diagnosing Pneumocystis carinii pneumonia | Q34943397 | ||
| Effect of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of P carinii pneumonia in patients with HIV-1: a prospective study | Q43718393 | ||
| Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in non-human immunodeficiency virus-infected patients: retrospective study of 31 patients | Q43757435 | ||
| Nosocomial Pneumocystis jirovecii pneumonia: lessons from a cluster in kidney transplant recipients. | Q43853029 | ||
| Concerns regarding data supporting recent Pneumocystis jirovecii prophylaxis guidelines | Q43968983 | ||
| Analysis of underlying diseases and prognosis factors associated with Pneumocystis carinii pneumonia in immunocompromised HIV-negative patients | Q44098040 | ||
| Molecular epidemiology linking multihospital clusters of opportunistic Pneumocystis jirovecii pneumonia | Q44526885 | ||
| Clindamycin with primaquine vs. Trimethoprim-sulfamethoxazole therapy for mild and moderately severe Pneumocystis carinii pneumonia in patients with AIDS: a multicenter, double-blind, randomized trial (CTN 004). CTN-PCP Study Group | Q44559214 | ||
| Pneumocystis carinii pneumonia complicating multiple myeloma | Q44823339 | ||
| Pneumocystis carinii pneumonia. Differences in lung parasite number and inflammation in patients with and without AIDS. | Q44990606 | ||
| Intravenous pentamidine is safe and effective as primary pneumocystis pneumonia prophylaxis in children and adolescents undergoing hematopoietic stem cell transplantation | Q45082408 | ||
| Pneumocystis carinii pneumonia in human immunodeficiency virus (HIV)-positive and HIV-negative immunocompromised patients | Q45745934 | ||
| Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment | Q46080510 | ||
| A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group | Q46482195 | ||
| Increased incidence of interstitial pneumonia by CHOP combined with rituximab | Q46647289 | ||
| Three cases of Pneumocystis jirovecii pneumonia (PCP) during first-line treatment with rituximab in combination with CHOP-14 for aggressive B-cell non-Hodgkin's lymphoma | Q46898582 | ||
| Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients | Q47620589 | ||
| Dihydropteroate synthase polymorphisms in Pneumocystis carinii | Q48054060 | ||
| Pneumocystis carinii pneumonia during steroid taper in patients with primary brain tumors | Q48341575 | ||
| Low absolute lymphocyte count and addition of rituximab confer high risk for interstitial pneumonia in patients with diffuse large B-cell lymphoma | Q48857119 | ||
| Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS) | Q52480275 | ||
| HRCT-features of Pneumocystis jiroveci pneumonia and their evolution before and after treatment in non-HIV immunocompromised patients. | Q53237068 | ||
| Comparison of clinical and radiological features of pneumocystis pneumonia between malignancy cases and acquired immunodeficiency syndrome cases: a multicenter study. | Q53309758 | ||
| Pneumocystis jiroveci pneumonia in patients with non-Hodgkin's lymphoma receiving chemotherapy containing rituximab. | Q53438572 | ||
| Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. | Q53538643 | ||
| Effects of mutations in Pneumocystis carinii dihydropteroate synthase gene on outcome of AIDS-associated P. carinii pneumonia. | Q54074344 | ||
| The increased risk for pneumocystis pneumonia in patients receiving rituximab-CHOP-14 can be prevented by the administration of trimethoprim/sulfamethoxazole: a single-center experience. | Q54333542 | ||
| Real-time PCR assay-based strategy for differentiation between active Pneumocystis jirovecii pneumonia and colonization in immunocompromised patients. | Q54406595 | ||
| Pneumocystis jirovecii pneumonia in B-cell lymphoma patients treated with the rituximab-CHOEP-14 regimen. | Q54561806 | ||
| Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients | Q56403277 | ||
| Oral dapsone versus nebulized pentamidine for Pneumocystis carinii pneumonia prophylaxis | Q57746388 | ||
| Outcomes of moderate-to-severe Pneumocystis pneumonia treated with adjunctive steroid in non-HIV-infected patients | Q35270593 | ||
| Prevention and treatment of pneumocystis pneumonia | Q35536707 | ||
| PCR diagnosis of Pneumocystis pneumonia: a bivariate meta-analysis | Q35599024 | ||
| Clinical significance of quantifying Pneumocystis jirovecii DNA by using real-time PCR in bronchoalveolar lavage fluid from immunocompromised patients | Q35689165 | ||
| African american primary care physicians' prostate cancer screening practices | Q36056432 | ||
| Risk factors analysis for Pneumocystis jiroveci pneumonia (PCP) in patients with haematological malignancies and pneumonia | Q36211354 | ||
| Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. | Q36349776 | ||
| Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). | Q36611825 | ||
| An analysis of the utilisation of chemoprophylaxis against Pneumocystis jirovecii pneumonia in patients with malignancy receiving corticosteroid therapy at a cancer hospital | Q36616349 | ||
| Pneumocystis carinii Pneumonia Among Patients Without AIDS at a Cancer Hospital | Q36746681 | ||
| Pneumocystis pneumonia in patients with HIV infection: clinical manifestations, laboratory findings, and radiological features | Q36749887 | ||
| Polymerase chain reaction detection of Pneumocystis jiroveci: evaluation of 9 assays. | Q36906353 | ||
| Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials | Q36931056 | ||
| Combined quantification of pulmonary Pneumocystis jirovecii DNA and serum (1->3)-β-D-glucan for differential diagnosis of pneumocystis pneumonia and Pneumocystis colonization | Q37264267 | ||
| Outbreak of pneumocystis pneumonia in renal and liver transplant patients caused by genotypically distinct strains of Pneumocystis jirovecii | Q37305589 | ||
| Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study | Q37417520 | ||
| Quantitative PCR to diagnose Pneumocystis pneumonia in immunocompromised non-HIV patients | Q37932857 | ||
| Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools | Q37944081 | ||
| Pneumocystis jirovecii pneumonia in non-HIV-infected patients in the era of novel immunosuppressive therapies | Q38032135 | ||
| Pneumocystis jirovecii pneumonia prophylaxis during temozolomide treatment for high-grade gliomas. | Q38038351 | ||
| Is caspofungin really an effective treatment for Pneumocystis jirovecii pneumonia in immunocompromised patients without human immunodeficiency virus infection? Experiences at a single center and a literature review. | Q38073854 | ||
| Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncol | Q38081793 | ||
| Late-onset Pneumocystis jirovecii pneumonia post-fludarabine, cyclophosphamide and rituximab: implications for prophylaxis | Q38106512 | ||
| Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia | Q39467565 | ||
| Pneumocystis carinii pneumonia. Review of 53 cases | Q39724057 | ||
| Molecular diagnosis of Pneumocystis jirovecii in patients with malignancy: clinical significance of quantitative polymerase chain reaction | Q40214531 | ||
| Phase II study of temozolomide and cisplatin as primary treatment prior to radiotherapy in newly diagnosed glioblastoma multiforme patients with measurable disease. A study of the Spanish Medical Neuro-Oncology Group (GENOM). | Q40516605 | ||
| Pneumocystis carinii pneumonia in patients with malignant haematological diseases: 10 years' experience of infection in GIMEMA centres. | Q40583859 | ||
| Successful Chemoprophylaxis forPneumocystis cariniiPneumonitis | Q41342669 | ||
| Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study | Q42212013 | ||
| Pneumocystis jirovecii pneumonia associated with gemcitabine chemotherapy: experience at an Australian center and recommendations for targeted prophylaxis | Q42225847 | ||
| Pneumocystis jirovecii pneumonia in HIV-negative patients: a prospective study with focus on immunosuppressive drugs and markers of immune impairment | Q42231929 | ||
| Single-day trimethoprim/sulfamethoxazole prophylaxis for Pneumocystis pneumonia in children with cancer. | Q42240047 | ||
| Interaction of Pneumocystis carinii dihydropteroate synthase with sulfonamides and diaminodiphenyl sulfone (dapsone). | Q42284628 | ||
| Intravenous or inhaled pentamidine for treating Pneumocystis carinii pneumonia in AIDS. A randomized trial | Q42633332 | ||
| A resurgence of Pneumocystis in aggressive lymphoma treated with R-CHOP-14: the price of a dose-dense regimen? | Q43109507 | ||
| High incidence of Pneumocystis jirovecii pneumonia in patients receiving biweekly rituximab and cyclophosphamide, adriamycin, vincristine, and prednisone | Q43109656 | ||
| Possible nosocomial transmission of Pneumocystis jirovecii | Q43180357 | ||
| Pneumocystis jiroveci pneumonia detected by FDG-PET. | Q43196834 | ||
| Addition of rituximab to cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy has a high risk of developing interstitial pneumonia in patients with non-Hodgkin lymphoma | Q43253520 | ||
| Fatal pneumocystis jiroveci pneumonia in ABVD-treated Hodgkin lymphoma patients | Q43273781 | ||
| Pneumocystis carinii pneumonia in patients with primary brain tumors | Q43458549 | ||
| A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii | Q43514860 | ||
| P433 | issue | 12b | |
| P921 | main subject | pneumonia | Q12192 |
| Pneumocystis jirovecii | Q134478 | ||
| P304 | page(s) | 1350-1363 | |
| P577 | publication date | 2014-12-01 | |
| P1433 | published in | Internal Medicine Journal | Q15749165 |
| P1476 | title | Consensus guidelines for diagnosis, prophylaxis and management of Pneumocystis jirovecii pneumonia in patients with haematological and solid malignancies, 2014. | |
| P478 | volume | 44 |
| Q49914898 | Adjuvant therapies in critical care: steroids to treat infectious diseases |
| Q52647071 | Birmingham vasculitis activity and chest manifestation at diagnosis can predict hospitalised infection in ANCA-associated vasculitis. |
| Q60929939 | Checkpoint inhibitors: What gastroenterologists need to know |
| Q50037034 | Combination of Echinocandins and Trimethoprim/Sulfamethoxazole for the Treatment of Pneumocystis jiroveci Pneumonia After Heart Transplantation |
| Q93088250 | Comparative Evaluation Between the RealStar Pneumocystis jirovecii PCR Kit and the AmpliSens Pneumocystis jirovecii (carinii)-FRT PCR Kit for Detecting P. jirovecii in Non-HIV Immunocompromised Patients |
| Q37623386 | Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia |
| Q35692811 | Cost-effectiveness of Prophylaxis Against Pneumocystis jiroveci Pneumonia in Patients with Crohn's Disease. |
| Q53393992 | Critical review of current clinical practice guidelines for antifungal therapy in paediatric haematology and oncology. |
| Q39450909 | Dapsone and azole interactions: A clinical perspective |
| Q42700853 | Diagnosis of Pneumocystis jirovecii pneumonia with serum cell-free DNA in non-HIV-infected immunocompromised patients |
| Q36437449 | Diagnosis of pneumocystis pneumonia using serum (1-3)-β-D-Glucan: a bivariate meta-analysis and systematic review |
| Q38934528 | ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients |
| Q59349040 | Evaluation of a Turbidimetric β-d-Glucan Test for Detection of Pneumocystis jirovecii Pneumonia |
| Q92502376 | Exploring failure of antimicrobial prophylaxis and pre-emptive therapy for transplant recipients: a systematic review |
| Q47646997 | Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision |
| Q39328076 | Immune Checkpoint Inhibitor-Induced Colitis: Diagnosis and Management |
| Q39430042 | Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities |
| Q41921482 | Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids. |
| Q52728829 | Infectious complications after hematopoietic stem cell transplantation: current status and future perspectives in Korea. |
| Q38284447 | Introduction to the updated Australian and New Zealand consensus guidelines for the use of antifungal agents in the haematology/oncology setting, 2014. |
| Q89481535 | Levofloxacin prophylaxis in patients with myeloma |
| Q91310935 | Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper |
| Q38940456 | Managing the oncologic patient with suspected pneumonia in the intensive care unit |
| Q38848880 | Pneumocystis jirovecii Pneumonia in the Non-HIV-Infected Population |
| Q48286433 | Pneumocystis jirovecii pneumonia in patients with acute myeloid leukaemia. |
| Q50100529 | Pneumocystis jirovecii pneumonia in patients with autoimmune diseases |
| Q100462412 | Pneumocystis jirovecii prophylaxis in neurosurgery |
| Q40758750 | Substantial variation in post-engraftment infection prophylaxis and revaccination practice in autologous stem cell transplant patients |
| Q93162646 | The Addition of Prophylactic Antibiotics Can Achieve a Favorable Outcome |
| Q40092648 | Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review. |
Search more.